FOLH1 and neoplasm: The tumor growthinhibition and median survival (TGDI2 = 4.2 ± 1.2; 36 days;Table 2) of mice that received 5.0 MBq161Tb-PSMA-617 indicated better therapy response thatthat achieved in previously-reported results obtained with 5.0 MBq177Lu-PSMA-617(TGDI2 = 2.1 ± 0.3, median survival: 32 days [34]).